Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 29;14:4575. doi: 10.1038/s41467-023-39816-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Ranking of 242 vaccinated individuals by their magnitude to SARS-CoV-2 Wuhan at enrollment. Each bar represents the magnitude of a single participant defined as the average response to the set Wuhan antigens (see Supplementary Data 5). Participants were divided into low (lowest quartile); mid (quartiles 2 + 3); and high (highest quartile) based on magnitude of IgA responses to Wuhan. b Spider plots of the average normalized responses in the low-baseline immune history (BIH) and high-BIH groups to a set of spike and receptor binding domain (RBD) proteins including the Wuhan spike and RBD, RBD mutants, and multiple SARS-CoV-2 variants of concern (see Supplementary Data 5) spike proteins. Responses of the low and high response groups of 127 uninfected individuals that received a fourth boost are plotted separately for IgA (top) and IgG (bottom). c Infectious-virus neutralization titers of 45 vaccinated uninfected individuals at day 0 and day 30 from the low-baseline (red) and high-baseline (teal) groups. Black lines denote the median. P-values were computed using the two-sided wilcoxon ranksum test.*p < 0.05; ***p < 0.0001; ****p < 0.00001. d Average IgA and IgG spider plots of 85 individuals that received 3 doses of the vaccine at day 0 (pink) and day 30 (green). Individuals were sorted by baseline response to SARS-CoV-2 variants of concern (VOC).